IssuerAnnouncementDetailsV2Portlet

Actions

Jamjoom Pharmaceuticals Factory Co. announces its Interim Financial Results for the Period Ending on 2023-06-30 ( Six Months )

4015
JAMJOOM PHARMA
0.28 %
1445/01/23     10/08/2023 09:32:46

Element ListCurrent QuarterSimilar quarter for previous year%ChangePrevious Quarter% Change
Sales/Revenue 298.4238.325.22302-1.19
Gross Profit (Loss) 198.1153.129.39199.6-0.75
Operational Profit (Loss) 92.657.660.7693.9-1.38
Net Profit (Loss) after Zakat and Tax 86.350.471.2384.42.25
Total Comprehensive Income 85.54974.4953.161.02
All figures are in (Millions) Saudi Arabia, Riyals
Element ListCurrent PeriodSimilar period for previous year%Change
Sales/Revenue 600.3482.124.52
Gross Profit (Loss) 397.7317.425.3
Operational Profit (Loss) 186.513538.15
Net Profit (Loss) after Zakat and Tax 170.79481.59
Total Comprehensive Income 138.691.551.48
Total Share Holders Equity (after Deducting Minority Equity) 1,354.91,2627.36
Profit (Loss) per Share 2.441.34
All figures are in (Millions) Saudi Arabia, Riyals
Element ListExplanation
The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is The Company’s net profit in the current quarter increased by 71.1% to reach SAR 86.3 million compared to SAR 50.4m for the similar quarter last year. This increase was mainly driven by:

1.Revenue increased by 25.2% due to increased demand of its products, new product launches; and the price adjustment for some of its key products

2.Selling and distribution expenses increased marginally by 1.1% vs 2Q 2022, despite the higher increase in revenue, this mitigation in the increase is mainly resulting from modification of commercial terms of a key distributor’s agreement in the later part of last year.

3.Finance charges reduced by 97.3% vs 2Q 2022 as the financial charges of 2Q 2022 includes a currency devaluation loss on the inter-company loan provided to the Company’s fully owned subsidiary in Egypt. In 4Q 2022, this loan was converted to a sub-ordinated perpetual equity instrument, therefore any currency devaluation beyond 4Q-2022 will not impact the Company’s Net Profit with regards to this arrangement with the subsidiary.

The reason of the increase (decrease) in the net profit during the current quarter compared to the previous quarter of the current year is Net profit slightly increased by 2.2% to reach SAR 86.3m in 2Q 2023 compared to SAR 84.4m in 1Q 2023. This was due to a the Company being able to maintain its sales growth levels achieved in 1Q 2023. The gross profit margin increased slightly whilst operating profit margin remained stable and the increase in net profit margin was mainly driven by a decrease in finance costs from SAR 2.2 million to SAR 0.1 million.
The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is The Company’s net profit in the current period increased by 81.7% to reach SAR 170.7 million in 1H 2023 compared to SAR 94.0m for the same period last year. This increase was mainly driven by:

1.Revenue increase of 24.5% due to greater demand for its products, the launch of new products and the price increases obtained for some of its key products toward the end of Q1 2023.

2.Selling and distribution expenses increases only by 10.7%, despite the higher increase in revenue, this mitigation in the increase mainly resulting from modification of commercial terms of a key distributor’s agreement in the later part of last year.

3.Finance Costs reduced by 97.3% during 1H 2023 as finance costs for 1H 2022 included the currency devaluation loss on the inter-company loan granted to the Company’s fully owned subsidiary in Egypt. In 4Q 2022, this loan was converted to a sub-ordinated perpetual equity instrument, therefore any currency devaluation beyond 4Q 2022 will not impact the Company’s Net Profit with regards to this arrangement with the subsidiary.

Statement of the type of external auditor's report Unmodified conclusion
Reclassification of Comparison Items Certain comparative figures have been reclassified to conform to the current period’s presentation.
Additional Information General Comments:

The Company’s financial position continued to be strong with zero debt. As of 30 June 2023, the Company had a cash balance of SAR 170.3 million, which represented an increase of 70.9% compared to the balance at 1H 2022. Significant changes in the Statement of Financial Position as at 30 June 2023 from 31 December 2022 were noted as follows:

1. Non-current assets decreased slightly by 2.7% driven mainly by the decrease in property, plant and equipment.

2. Current assets increased by 33.8% mainly due to an increase in trade receivables and inventories.

3. Current liabilities increased by 54.5% mainly due to an increase in trade payables and other current liabilities.

4. Non-current liabilities increased by 8.6% mainly due to an increase in provision for employee benefits.

5. Shareholders' equity increased by 11.4% driven by the increase in retained earnings partially offset by decrease in the foreign currency reserve.

Attached Documents  

The Capital Market Authority and Saudi Exchange take no responsibility for the contents of this disclosure, make no representations as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this disclosure, and the issuer accepts full responsibility for the accuracy of the information contained in it and confirms, having made all reasonable enquiries, that to the best of their knowledge and belief, there are no other facts or information the omission of which would make the disclosure misleading, incomplete or inaccurate.

Company Performance

JAMJOOM PHARMA
Add To Watchlist
In your Watchlist
Add To Watchlist
Key Parameters
Last Price 141.0
Net Change 0.4 (+0.28%)
Value Traded (Sar) 13,641,285.8
Volume Traded 97,804
See The Company Profile

LoginPortletPopupv2

Actions

AddtoWatchlistv2

Actions

Add to watchlist